← Human Trials & Peer-Reviewed Studies
Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial
Plain-language guide to PMID 37264767 (2023): placebo-controlled randomized controlled trial study of Liraglutide in 251 adolescents, fat loss, obesity & body recomposition.
Key Facts
- PMID
- 37264767
- Journal
- Pediatric obesity
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Bensignor MO et al. (10 authors)
- DOI
- 10.1111/ijpo.13061
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Liraglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.
Who Took Part
The abstract describes 251 adolescents taking part.
By PubMed's age tags, the people studied were children, teenagers and adults.
I), severity of depression symptoms (Patient Health Questionnaire-9), and weight variability (weight fluctuations over time).
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.
Some adolescents received a placebo instead of Liraglutide, giving a reference point.
A time span of 56 weeks appears in the methods.
Logistic regression analysis was performed in 251 adolescents treated with liraglutide (n = 125) or placebo (n = 126) for 56 weeks.
Baseline characteristics (selected a priori) included sex, race, ethnicity, age, Tanner (pubertal) stage, glycemic status (hyperglycemia [type 2 diabetes/prediabetes] vs. normoglycemia), obesity category (Class II/III vs.
What Was Measured
Topics PubMed links to this paper include Anti-Obesity Agents, Diabetes Mellitus, Type 2, Liraglutide, Pediatric Obesity and Weight Loss.
Author keywords: anti-agents, glucagon-like peptide-1 receptor agonists, paediatric obesity and weight management.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Liraglutide in 251 adolescents in people with fat loss, obesity & body recomposition over 56 weeks.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Pediatric obesity), a journal based in England.
More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.